Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
brain ischemia/ödem
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 26 Ergebnisse
Methods of using L-butylphthalide for the prevention and treatment of cerebral ischemia disease
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The inventive subject matter relates to a new use of L-butylphthalide in the prevention and treatment of cerebral ischemia-induced diseases, particularly to a use of L-butylphthalide in manufacturing the medicaments for the prevention and treatment of cerebral ischemia-induced
Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
STATEMENT REGARDING FEDERAL SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The disclosure generally relates to the field of Neurology. More particularly, it relates to compositions and methods for treat neurological diseases associated with an increase in the permeability of the blood brain barrier (BBB), cerebral edema and/or cell death.
BACKGROUND
Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Stroke remains the third most common cause of death in the industrial world, ranking behind ischemic heart disease and cancer. Strokes are responsible for about 300,000 deaths annually in the United States and about 11,000 deaths annually in Austria. Strokes are also a
Substituted spirobenzazepines
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects
Substituted spiroheterocycles
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
Substituted spiroheterocycles
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
Use of timosaponin Bll in the preparation of a medicament or product for the prevention and treatment of stroke
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to use of timosaponin BII, in particular the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke (apoplexy).
BACKGROUND ART
Stroke (apoplexy) involves sudden loss of neural function due to
Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to the use of N-acetyl-D-glucosamine and pharmaceutical acceptable salts thereof in the manufacture of a medicament for resisting cardiac and cerebral ischemia as well as oxygen-deficiency.
BACKGROUND ART
The cardiac and cerebral ischemia as well as
Triaza-cyclopenta[cd]indene derivatives
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
This Application is a 371 of PCT/JP2005/000323, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is
Pyrrolopyrimidine and pyrrolotriazine derivatives
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
This Application is a 371 of PCT/JP2005/000319, filed Jan. 6, 2005.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety,
Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
This Application is a 371 of PCT/JP2005/000318, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is
Pyrrolopyridine derivatives substituted with cyclic amino group
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating
Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating
Prodrug amino acid derivative
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to prodrugs of (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarb- oxylic acid derivatives and (1S,2R,3R,5R,6S)-2-amino-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives useful as drugs. More specifically, the present
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
